?one prior regimen of chemotherapy for State-of-the-art breast cancer and throughout the complete trial, prior publicity to any FGFR inhibitor, big surgical procedure or radiotherapy in four months previous to initial dose of research procedure and having strong inhibitors or inducers of CYP3A4 or CYP2D6. Any of the next cardiac requirements preclu